Express Pharma
APRIL 25, 2024
In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy.
pharmaphorum
AUGUST 2, 2022
The trial involved cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who were getting treatment with Tecentriq second-line after earlier platinum-based chemotherapy failed. Results from a trial in first-line NSCLC are due in early 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
FEBRUARY 19, 2024
Thomas Wales, Oncology Analyst at GlobalData, comments, “While the CRC market will see steady growth throughout the forecast period, the patent expiry of MSD’s popular immunotherapy Keytruda (pembrolizumab) in 2028 is expected to cause some contraction in the market.
pharmaphorum
SEPTEMBER 13, 2022
While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century. 1942 – Chemotherapy moves from trenches to treatment .
Pharmaceutical Technology
OCTOBER 5, 2022
According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.
Pharmaceutical Technology
AUGUST 16, 2022
Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.
Pharmaceutical Technology
MARCH 30, 2023
On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. billion in 2028. This announcement is not the only recent development for Keytruda.
Expert insights. Personalized for you.
116 
Let's personalize your content